Mostrar el registro sencillo del ítem
dc.contributor.author
Garrido, David
dc.contributor.author
Slavutsky, Irma Rosa
dc.contributor.author
Riva, Eloisa
dc.contributor.author
Grupo de Estudio Latinoamericano de Mieloma Múltiple
dc.date.available
2024-02-22T11:27:37Z
dc.date.issued
2023-02
dc.identifier.citation
Garrido, David; Slavutsky, Irma Rosa; Riva, Eloisa; Grupo de Estudio Latinoamericano de Mieloma Múltiple; Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting; Mosby-Elsevier; Current Problems In Cancer; 47; 1; 2-2023; 1-8
dc.identifier.issn
0147-0272
dc.identifier.uri
http://hdl.handle.net/11336/227948
dc.description.abstract
Cytogenetic abnormalities (CA) such as t(4;14), t(14;16), and del(17p), are associated with a poor prognosis in Multiple Myeloma (MM) patients. However, there is scarce information regarding the Latin-American population. This study aims to analyze the impact of t(4;14), t(14;16), and del(17p) on the progression-free survival (PFS) and overall survival (OS) of transplant-eligible newly-diagnosed MM (NDMM) patients in Latin America. Retrospective survival analysis based on the Grupo de Estudio Latinoamericano de MM (GELAMM) registry, including all adult patients with NDMM harboring CA t(4;14), t(14;16), and/or del(17p). Fifty-nine patients were included; the median age was 57 years, 55.9% males, 22% ISS-I, 25.4% ISS-II, and 47.5% ISS-III. The majority (89.8%) had one alteration, whereas 10.2% had del(17p) and t(4;14). The frequencies of CA were del(17p) in 61.0%, t(4;14) in 25.4%, and t(14;16) in 3,4%. Autologous stem cell transplantation was performed in 36 cases, 20 patients did not use this consolidative strategy, and this data was missed in three cases. Five-year OS for the entire cohort was 60.8% and 5-year PFS was 28.1%. Bortezomib-based induction regimen (BBR) (p=0.029), consolidation with ASCT (p<0.001), and maintenance therapy (p=0.004) were associated with an improved 5-year OS. In the multivariate analysis, ASCT was the only variable with a positive impact on OS (HR 0.11, 95% CI 0.033 to 0.34, p<0.001). The median PFS presented a non-statistically significant benefit in BBR, ASCT, and maintenance therapy groups. BBR induction, ASCT, and maintenance therapy were associated with improved OS in high-risk NDMM patients.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Mosby-Elsevier
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
CHROMOSOME ABERRATIONS
dc.subject
HEMATOPOIETIC STEM CELL TRANSPLANTATION
dc.subject
MULTIPLE MYELOMA
dc.subject
SURVIVAL
dc.subject.classification
Hematología
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-02-20T12:56:09Z
dc.journal.volume
47
dc.journal.number
1
dc.journal.pagination
1-8
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Garrido, David. Universidad de la República. Facultad de Medicina. Hospital de Clínicas "Dr. Manuel Quintela"; Uruguay
dc.description.fil
Fil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
dc.description.fil
Fil: Riva, Eloisa. Universidad de la República. Facultad de Medicina. Hospital de Clínicas "Dr. Manuel Quintela"; Uruguay
dc.description.fil
Fil: Grupo de Estudio Latinoamericano de Mieloma Múltiple. No especifíca;
dc.journal.title
Current Problems In Cancer
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0147027222000757
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.currproblcancer.2022.100916
Archivos asociados